81 related articles for article (PubMed ID: 16824748)
1. Mutational analysis of the hCDC4 gene in gastric carcinomas.
Lee JW; Soung YH; Kim HJ; Park WS; Nam SW; Kim SH; Lee JY; Yoo NJ; Lee SH
Eur J Cancer; 2006 Sep; 42(14):2369-73. PubMed ID: 16824748
[TBL] [Abstract][Full Text] [Related]
2. The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling.
Malyukova A; Dohda T; von der Lehr N; Akhoondi S; Corcoran M; Heyman M; Spruck C; Grandér D; Lendahl U; Sangfelt O
Cancer Res; 2007 Jun; 67(12):5611-6. PubMed ID: 17575125
[TBL] [Abstract][Full Text] [Related]
3. Cyclin E gene (CCNE) amplification and hCDC4 mutations in endometrial carcinoma.
Cassia R; Moreno-Bueno G; Rodríguez-Perales S; Hardisson D; Cigudosa JC; Palacios J
J Pathol; 2003 Dec; 201(4):589-95. PubMed ID: 14648662
[TBL] [Abstract][Full Text] [Related]
4. hCDC4 gene mutations in endometrial cancer.
Spruck CH; Strohmaier H; Sangfelt O; Müller HM; Hubalek M; Müller-Holzner E; Marth C; Widschwendter M; Reed SI
Cancer Res; 2002 Aug; 62(16):4535-9. PubMed ID: 12183400
[TBL] [Abstract][Full Text] [Related]
5. hCDC4 gene mutation is rare in colorectal carcinomas in Korean patients.
Lee JW; Jeong EG; Lee SH; Yoo NJ; Lee SH
Pathology; 2008 Apr; 40(3):305. PubMed ID: 18428053
[No Abstract] [Full Text] [Related]
6. hCDC4 variation in osteosarcoma.
Yan T; Wunder JS; Gokgoz N; Seto KK; Bell RS; Andrulis IL
Cancer Genet Cytogenet; 2006 Sep; 169(2):138-42. PubMed ID: 16938571
[TBL] [Abstract][Full Text] [Related]
7. Somatic mutation of hCDC4 gene is rare in lung adenocarcinomas.
Woo Lee J; Hwa Soung Y; Young Kim S; Woo Nam S; Sang Park W; Young Lee J; Jin Yoo N; Hyung Lee S
Acta Oncol; 2006; 45(4):487-8. PubMed ID: 16760187
[No Abstract] [Full Text] [Related]
8. MicroRNA-223 functions as an oncogene in human gastric cancer by targeting FBXW7/hCdc4.
Li J; Guo Y; Liang X; Sun M; Wang G; De W; Wu W
J Cancer Res Clin Oncol; 2012 May; 138(5):763-74. PubMed ID: 22270966
[TBL] [Abstract][Full Text] [Related]
9. The Fbxw7/hCdc4 tumor suppressor in human cancer.
Tan Y; Sangfelt O; Spruck C
Cancer Lett; 2008 Nov; 271(1):1-12. PubMed ID: 18541364
[TBL] [Abstract][Full Text] [Related]
10. Infrequent mutations of Archipelago (hAGO, hCDC4, Fbw7) in primary ovarian cancer.
Kwak EL; Moberg KH; Wahrer DC; Quinn JE; Gilmore PM; Graham CA; Hariharan IK; Harkin DP; Haber DA; Bell DW
Gynecol Oncol; 2005 Jul; 98(1):124-8. PubMed ID: 15913747
[TBL] [Abstract][Full Text] [Related]
11. Inactivation of hCDC4 can cause chromosomal instability.
Rajagopalan H; Jallepalli PV; Rago C; Velculescu VE; Kinzler KW; Vogelstein B; Lengauer C
Nature; 2004 Mar; 428(6978):77-81. PubMed ID: 14999283
[TBL] [Abstract][Full Text] [Related]
12. Mutation of hCDC4 leads to cell cycle deregulation of cyclin E in cancer.
Ekholm-Reed S; Spruck CH; Sangfelt O; van Drogen F; Mueller-Holzner E; Widschwendter M; Zetterberg A; Reed SI
Cancer Res; 2004 Feb; 64(3):795-800. PubMed ID: 14871801
[TBL] [Abstract][Full Text] [Related]
13. FBXW7 mutation in adult T-cell and B-cell acute lymphocytic leukemias.
Song JH; Schnittke N; Zaat A; Walsh CS; Miller CW
Leuk Res; 2008 Nov; 32(11):1751-5. PubMed ID: 18485478
[TBL] [Abstract][Full Text] [Related]
14. Low frequency of hCDC4 mutations in human primary ovarian cancer.
Sgambato A; Cittadini A; Masciullo V; Di Salvatore M; Graziani C; Rettino A; Valdivieso P; Scambia G; Bianchino G; Zupa A; Improta G; Cifarelli RA
Gynecol Oncol; 2007 May; 105(2):553-5. PubMed ID: 17320938
[No Abstract] [Full Text] [Related]
15. FBXW7/hCDC4 is a general tumor suppressor in human cancer.
Akhoondi S; Sun D; von der Lehr N; Apostolidou S; Klotz K; Maljukova A; Cepeda D; Fiegl H; Dafou D; Marth C; Mueller-Holzner E; Corcoran M; Dagnell M; Nejad SZ; Nayer BN; Zali MR; Hansson J; Egyhazi S; Petersson F; Sangfelt P; Nordgren H; Grander D; Reed SI; Widschwendter M; Sangfelt O; Spruck C
Cancer Res; 2007 Oct; 67(19):9006-12. PubMed ID: 17909001
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer.
Akhoondi S; Lindström L; Widschwendter M; Corcoran M; Bergh J; Spruck C; Grandér D; Sangfelt O
Breast Cancer Res; 2010; 12(6):R105. PubMed ID: 21122106
[TBL] [Abstract][Full Text] [Related]
17. Genetic susceptibility to the development and progression of breast cancer associated with polymorphism of cell cycle and ubiquitin ligase genes.
Yu JC; Ding SL; Chang CH; Kuo SH; Chen ST; Hsu GC; Hsu HM; Hou MF; Jung LY; Cheng CW; Wu PE; Shen CY
Carcinogenesis; 2009 Sep; 30(9):1562-70. PubMed ID: 19587092
[TBL] [Abstract][Full Text] [Related]
18. CDC4 mutations occur in a subset of colorectal cancers but are not predicted to cause loss of function and are not associated with chromosomal instability.
Kemp Z; Rowan A; Chambers W; Wortham N; Halford S; Sieber O; Mortensen N; von Herbay A; Gunther T; Ilyas M; Tomlinson I
Cancer Res; 2005 Dec; 65(24):11361-6. PubMed ID: 16357143
[TBL] [Abstract][Full Text] [Related]
19. Mutational analysis of the CASP6 gene in colorectal and gastric carcinomas.
Lee JW; Kim MR; Soung YH; Nam SW; Kim SH; Lee JY; Yoo NJ; Lee SH
APMIS; 2006 Sep; 114(9):646-50. PubMed ID: 16948818
[TBL] [Abstract][Full Text] [Related]
20. Frameshift mutations of ATBF1, WNT9A, CYLD and PARK2 in gastric and colorectal carcinomas with high microsatellite instability.
An CH; Kim SS; Kang MR; Kim YR; Kim HS; Yoo NJ; Lee SH
Pathology; 2010; 42(6):583-5. PubMed ID: 20854080
[No Abstract] [Full Text] [Related]
[Next] [New Search]
